Aerie Pharmaceuticals Inc (AERI) Receives Average Recommendation of “Buy” from Analysts

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) have earned an average recommendation of “Buy” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and thirteen have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $71.77.

AERI has been the topic of a number of research analyst reports. Mizuho restated a “buy” rating and issued a $70.00 price target on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Needham & Company LLC restated a “buy” rating and issued a $76.00 price target (up from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Canaccord Genuity restated a “positive” rating and issued a $73.00 price target (up from $65.00) on shares of Aerie Pharmaceuticals in a report on Monday, October 16th. Guggenheim initiated coverage on shares of Aerie Pharmaceuticals in a report on Monday, October 23rd. They issued a “buy” rating and a $80.00 price target on the stock. Finally, Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Aerie Pharmaceuticals by 55.0% during the 2nd quarter. Vanguard Group Inc. now owns 2,158,825 shares of the company’s stock worth $113,446,000 after acquiring an additional 766,300 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Aerie Pharmaceuticals by 11.5% in the 4th quarter. Bank of New York Mellon Corp now owns 613,305 shares of the company’s stock valued at $36,645,000 after buying an additional 63,030 shares in the last quarter. Columbus Circle Investors boosted its holdings in shares of Aerie Pharmaceuticals by 41.0% in the 3rd quarter. Columbus Circle Investors now owns 519,806 shares of the company’s stock valued at $25,263,000 after buying an additional 151,133 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Aerie Pharmaceuticals by 6.6% in the 2nd quarter. Northern Trust Corp now owns 405,116 shares of the company’s stock valued at $21,289,000 after buying an additional 25,254 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its holdings in shares of Aerie Pharmaceuticals by 67.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 388,666 shares of the company’s stock valued at $18,889,000 after buying an additional 156,056 shares in the last quarter. Institutional investors own 97.89% of the company’s stock.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded down $1.00 on Friday, hitting $52.55. 570,475 shares of the stock traded hands, compared to its average volume of 417,092. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. The stock has a market capitalization of $2,018.50, a P/E ratio of -15.73 and a beta of 0.87. Aerie Pharmaceuticals has a 1-year low of $38.14 and a 1-year high of $66.60.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.89) EPS for the quarter. sell-side analysts forecast that Aerie Pharmaceuticals will post -3.97 EPS for the current year.

TRADEMARK VIOLATION WARNING: This news story was originally posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/10/aerie-pharmaceuticals-inc-aeri-receives-average-recommendation-of-buy-from-analysts.html.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply